AzTrials
AzTrials

ObesityNCT02026414

Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)

A study testing PrimaVie and Exercise in people with Obesity, run by Sanni Raju at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging. Read more about this study

Who is it for?
Ages 21 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Obesity
What is being tested?
PrimaVie and Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
29 participants
Where
1 siteUnited States
Study dates
Jan 2014to Jun 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients 21-70 years of age
  • BMI 25-34.9

Who cannot join

  • BMI >35 OR < 25
  • Individuals who are deemed unable to understand the procedures, risks and benefits of the study,( i.e. Informed consent) will be excluded
  • Females who are pregnant as well as individuals who are therapeutically immuno-compromised will also be excluded in order to minimize the risk to such individuals (and fetus); to decrease statistical variability and to minimize potential of confounders.
  • Candidates for inclusion into the study will not include individuals as defined in 45 CFR 46 Subparts B, C and D, nor from any other population which may be considered vulnerable. Pregnant women are excluded to minimize the risk to such individuals (and fetus); to decrease statistical variability and to minimize potential of confounders.
  • History of MRSA (Methicillin-resistant Staphylococcus aureus)
  • Current use of any of the following medications will result in exclusion:
Show all 15Show fewer
  • Steroids (Prednisone, etc.)
  • Beta-Blockers
  • Immunosuppressants
  • Hydrochlorothiazide
  • Statins (Crestor, Lipitor, etc.)
  • Aspirin
  • ACE Inhibitors
  • Accutane (within the last 6 months)
  • Muscle relaxants and stimulants

Trial locations and contacts

1 site in 1 country.

United States1 site
  • The Ohio State University Wexner Medical Center (Davis Heart and Lung Research Institute)

    Columbus, Ohio, 43210

Other trials in United States

About this study

Official title: Effects of PrimaVie and Exercise Training on Human Skeletal Muscle Adaptation

PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging. Findings on a recent murine study revealed that PrimaVie (PV) significantly changed the expression of genes related to muscle function (unpublished data). Based on these facts, it was thought of interest to study the effect of PrimaVie and exercise training on human skeletal muscle adaptation.

The objective of the study is to determine effect of PrimaVie supplementation and combined PrimaVie supplementation and exercise on changes in muscle gene expression related to muscle function. Two hypothesizes have been made, oral supplementation of PrimaVie twice a day for 12 weeks will influence gene expression in the skeletal muscle of pre-obese to obese humans, oral supplementation of PV will act with treadmill exercise training to favorably impact skeletal muscle gene expression. The participants will have a total of 3 visits over 12 weeks. During each visit will include measurement of height, weight and vital signs, 2 tablespoons of blood will be draw from left or right arm, and muscle biopsies (using biopsy needle) will be collected under the use of local anesthetics. The blood and muscle biopsies will be used for all lab related procedure.

Read the detailed description

Potential subjects will see an advertisement placed in locations around the Wexner Medical Center with RN (research nurse) listed as the main contact. After potential subjects contact the research nurse, he/she will use inclusion/exclusion criteria to determine potential eligibility. If the potential subject meets all inclusion/exclusion criteria, he/she will be scheduled for a primary visit at the Morehouse Medical Plaza or Davis Heart and Lung Research Institute. At this initial visit, the research nurse will meet the potential subject in a private room where the study will be fully explained in lay language, and informed consent will be obtained. Then, appropriate demographic, biometric and health/clinical information will be recorded on the data collection sheet, and 22.5 mL of blood will be obtained via venipuncture in the right/ left forearm. A muscle biopsy will also be collected by a trained physician. The blood and muscle biopsy will be used for all lab related study procedures. The subjects will be given an 8-week supply of the PrimaVie supplement with instructions, as well as a copy of the research protocol and informed consent form. If the supplements are mailed, they will also have instructions, as well as a copy of the research protocol and informed consent form mailed. The subject will be instructed to call the Research Nurse/ approved study personnel to let them know that they have received the supplements by mail and to go over any questions or concerns the subject may have as well as to schedule follow up visits. All follow up visits (T1, T2, T3a and T3b) will consist of a 22.5 mL blood draw, collection of muscle biopsy/biopsies and measurement of previously specified demographic, biometric and health/clinical variables.

For 4 weeks of exercise treadmill training (70-75% HRmax for 20 mins; 5 min warm up and 5 min cool down - total 30 mins a day; 3 days a week), the subjects will be doing supervised (study personnel) exercise routine (Treadmill) at study designated facilities( located on The Ohio State University campus).

Study Hypotheses:

  • Hypothesis 1: That oral supplementation of PrimaVie twice a day for 12 weeks will influence gene expression in the skeletal muscle of sedentary pre-obese to obese humans
  • Hypothesis 2: That oral supplementation of PrimaVie will synergistically act with treadmill exercise training to favorably impact skeletal muscle gene expression.

Aim: A non-randomized, longitudinal study to determine the effect of PrimaVie and exercise training on human skeletal muscle adaptation in 30 pre-obese to obese volunteers.

Participants: 40 volunteers will be recruited via study advertisement, and contact the research staff based on the study inclusion and exclusion criteria. At each visit the following will be recorded/collected:

  • 22.5 mL of blood (approximately 2 tablespoons) (venipuncture)
  • Muscle biopsy/biopsies (1 muscle biopsy per visit collected at T1 and T2, and 2 muscle biopsies are collected at T3)
  • Age (years)
  • Sex (M/F)
  • Height (cm)
  • Weight (lbs)
  • BMI (Kg/m2)
  • Blood pressure (mm/Hg)
  • Pulse
  • Body fat Percentage
  • During the first visit (enrollment visit, T1), the following information will be recorded/collected as well:
  • Tobacco use history
  • Current alcohol use
  • Current other drug use
  • Current exercise regimen
  • Date of first day of last menstrual period (for females only)
  • Current Medications
  • Allergies
  • Nonmedical information, including: address (will be used to send PrimaVie supplement via mail, when applicable); telephone number, and email address

Participants will come for three visits:

  • Visit 1 (T1) - Baseline (prior to the start of supplementation)
  • Visit 2 (T2) - First 8 weeks of supplementation alone
  • Visit 3 (T3) - Next 4 weeks of supplementation together with exercise (T3 consists of 2 sample collections: T3a (pre-exercise) after 12 weeks of supplementation together with 4 weeks of exercise - samples taken immediately before the final exercise routine (during Visit 3), and T3b (post exercise) after 12 weeks of supplementation together with 4 weeks of exercise immediately after the final exercise routine (during Visit 3)

Samples collected from participants:

  • Peripheral blood: At all visits, 22.5 mL of peripheral venous blood will be collected.
  • Muscle biopsies: biopsies will be collected from the Vastus lateralis or Gastrocnemius muscles. A biopsy will be collected by a board certified Physician after application of local anesthetic to the site of biopsy.

Study Supplement: PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging. PrimaVie® also works at the cellular level, playing a direct role in the synthesis of ATP, a compound that supplies the body with energy, and healthy mitochondrial function. Findings on a recent murine study revealed that PrimaVie (PV) significantly changed the expression of genes related to muscle function (unpublished data). Based on these facts, it was thought of interest to study the effect of PrimaVie and exercise training on human skeletal muscle adaptation. Participants will take:

  • 500 mg/day PrimaVie (Natreon Inc.) supplement, 250 twice a day for the first 8 weeks of the study( a 250 mg capsule in the morning with food and a 250 mg capsule in the evening with food)
  • 500 mg/day PrimaVie (Natreon Inc) supplement, 250 mg twice a day for the next 4 weeks (a 250 mg capsule in the morning with food and a 250 mg capsule in the evening with food) of the study while including supervised exercise treadmill training, which includes:
  • exercise supervised treadmill training (supervised treadmill training which include a 5 minute warm up; 70-75% HRmax for 20 minutes; and a 5 minute cool down - a total 30 minutes per day for 3 days per week)
Conditions
Obesity
Being tested
PrimaVie, Exercise
Keywords
PrimaVie, Herbal Supplement, Muscle biopsy, Energy, Exercise, Human skeletal muscle adaptation, Muscle function
Medical subject headings
Obesity, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PrimaVieDietary supplement

    Also called purified and standardized shilajit extract

    Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.

  • ExerciseOther

Study groups in NCT02026414
Study groupRoleWhat they receive
PrimaVie ExerciseExperimentalSubjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
Receives: Dietary Supplement: PrimaVie; Other: Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood plasma assay

    Plasma creatine kinase (U/ml) myoglobin (ng/ml) troponin (ug/L) plasma glucose (mg/dl) lipid profiles (mg/dl) ATP levels (umol/L)

    Plasma creatine kinase, myoglobin, ATP and troponin will indicate muscle damage (these are "muscle damage markers").

    Measured: 12 Weeks

Secondary outcomes (1)
  1. Muscle Biopsy Results

    Biopsies from the Vastus lateralis or Gastrocnemius muscles will be used for miRNA expression profiling (au) mRNA (delta Ct or fold change) protein determinations (fold change)

    Measured: 12 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionJun 2018
  4. Study completionJun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
29 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02026414
Sponsor's protocol ID
20131230
Status last verified
Jun 2022
First submitted
16 Dec 2013
Last updated
1 Jul 2022
Results posted
No
Data monitoring committee
No

Publications

  • Das A, Datta S, Rhea B, Sinha M, Veeraragavan M, Gordillo G, Roy S. The Human Skeletal Muscle Transcriptome in Response to Oral Shilajit Supplementation. J Med Food. 2016 Jul;19(7):701-9. doi: 10.1089/jmf.2016.0010.

    PubMed 27414521

Questions about this trial

What is this clinical trial studying?

A study testing PrimaVie and Exercise in people with Obesity, run by Sanni Raju at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood plasma assay (time frame: 12 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02026414, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in